Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRA | P19793 | 1/20 | 0.51 |
| ▸ | RXRB | P28702 | 1/20 | 0.51 |
| ▸ | RXRG | P48443 | 1/20 | 0.51 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.47 |
| ▸ | CCNE2 | O96020 | 1/20 | 0.47 |
| ▸ | CDK1 | P06493 | 1/20 | 0.47 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.47 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.47 |
| ▸ | CDK2 | P24941 | 1/20 | 0.47 |
| ▸ | CCNB3 | Q8WWL7 | 1/20 | 0.47 |
| ▸ | MRGPRX4 | Q96LA9 | 3/20 | 0.45 |
| ▸ | PPARG | P37231 | 1/20 | 0.45 |
| ▸ | SRD5A2 | P31213 | 2/20 | 0.45 |
| ▸ | MAOB | P27338 | 1/20 | 0.45 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7100827 | 0.87 | RXRA (0.55) | RXRARXRBRXRGMRGPRX4PTPN1 | |
| SCHEMBL1638876 | 0.86 | RXRA (0.50) | RXRARXRBRXRGMRGPRX4MAOB | |
| SCHEMBL1638990 | 0.85 | FFAR1 (0.47) | RXRARXRBRXRGCCNB2CCNE2 | |
| SCHEMBL27894248 | 0.84 | RXRA (0.48) | RXRARXRBRXRGMRGPRX4PTPN1 | |
| SCHEMBL12646937 | 0.83 | CCNE2 (0.46) | RXRACCNB2CCNE2CDK1CCNB1 | |
| SCHEMBL1643862 | 0.82 | NR1H4 (0.46) | RXRARXRBRXRGLMNAHPGD | |
| SCHEMBL12725987 | 0.79 | CCNB2 (0.50) | CCNB2CCNE2CDK1CCNB1CCNE1 | |
| SCHEMBL1638569 | 0.78 | PTGER1 (0.50) | RXRARXRBRXRGCCNB2CCNE2 | |
| SCHEMBL8460349 | 0.77 | RXRA (0.72) | RXRARXRBRXRGMRGPRX4HPGD | |
| SCHEMBL1637804 | 0.77 | TDP1 (0.48) | RXRARXRBRXRGMRGPRX4MAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8557936-B2 | Catalyst compounds and use thereof | EXXONMOBIL CHEMICAL PATENTS INC. (US) | 2013-10-15 | — | — | US | disclosed |
| US-8557936-B2 | Catalyst compounds and use thereof | EXXONMOBIL CHEMICAL PATENTS INC. (US) | 2013-10-15 | — | — | US | disclosed |
| US-8541522-B2 | Catalyst compounds and use thereof | EXXONMOBIL CHEMICAL PATENTS INC. (US) | 2013-09-24 | — | — | US | disclosed |
| US-8541522-B2 | Catalyst compounds and use thereof | EXXONMOBIL CHEMICAL PATENTS INC. (US) | 2013-09-24 | — | — | US | disclosed |
| EP-2493932-A2 | CATALYST COMPOUNDS AND USE THEREOF | ExxonMobil Chemical Patents Inc. (US) | 2012-09-05 | — | — | EP | disclosed |
| EP-2493934-A2 | CATALYST COMPOUNDS AND USE THEREOF | ExxonMobil Chemical Patents Inc. (US) | 2012-09-05 | — | — | EP | disclosed |
| WO-2011056428-A2 | CATALYST COMPOUNDS AND USE THEREOF | EXXONMOBIL CHEMICAL PATENTS INC. (US) | 2011-05-12 | — | — | WO | disclosed |
| WO-2011056423-A2 | CATALYST COMPOUNDS AND USE THEREOF | EXXONMOBIL CHEMICAL PATENTS INC. (US) | 2011-05-12 | — | — | WO | disclosed |
| US-20110098425-A1 | Catalyst Compounds and Use Thereof | EXXONMOBIL CHEMICAL PATENTS INC. | 2011-04-28 | — | — | US | disclosed |
| US-20110098429-A1 | Catalyst Compounds and Use Thereof | EXXONMOBIL CHEMICAL PATENTS INC. | 2011-04-28 | — | — | US | disclosed |
| US-20110098425-A1 | Catalyst Compounds and Use Thereof | EXXONMOBIL CHEMICAL PATENTS INC. | 2011-04-28 | — | — | US | disclosed |
| US-20110098429-A1 | Catalyst Compounds and Use Thereof | EXXONMOBIL CHEMICAL PATENTS INC. | 2011-04-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110098425-A1 | Catalyst Compounds and Use Thereof | ALOX12, THEM6, ALOX15 | RXRA 1872/4885RXRB 2650/4885RXRG 1605/4885 |
| US-20110098429-A1 | Catalyst Compounds and Use Thereof | ALOX12, THEM6, ALOX15 | RXRA 1872/4885RXRB 2650/4885RXRG 1605/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.